Sectoral Asset Management Inc. Lowers Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Sectoral Asset Management Inc. lowered its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYSFree Report) by 28.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 605,606 shares of the company’s stock after selling 235,153 shares during the quarter. Mineralys Therapeutics comprises 2.2% of Sectoral Asset Management Inc.’s investment portfolio, making the stock its 10th largest holding. Sectoral Asset Management Inc. owned approximately 1.47% of Mineralys Therapeutics worth $5,208,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Federated Hermes Inc. boosted its holdings in Mineralys Therapeutics by 8.3% in the 3rd quarter. Federated Hermes Inc. now owns 22,293 shares of the company’s stock valued at $212,000 after purchasing an additional 1,700 shares during the period. CWM LLC boosted its position in shares of Mineralys Therapeutics by 120.0% during the 4th quarter. CWM LLC now owns 5,891 shares of the company’s stock valued at $51,000 after acquiring an additional 3,213 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Mineralys Therapeutics in the 4th quarter worth approximately $41,000. SG Americas Securities LLC bought a new position in shares of Mineralys Therapeutics during the 4th quarter valued at about $87,000. Finally, CreativeOne Wealth LLC purchased a new position in shares of Mineralys Therapeutics during the 4th quarter valued at about $92,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Mineralys Therapeutics Stock Down 2.3 %

Shares of Mineralys Therapeutics stock traded down $0.31 on Friday, hitting $13.14. The stock had a trading volume of 60,549 shares, compared to its average volume of 91,932. Mineralys Therapeutics, Inc. has a one year low of $5.85 and a one year high of $17.44. The stock’s 50-day simple moving average is $12.69 and its two-hundred day simple moving average is $11.43. The stock has a market cap of $652.40 million, a price-to-earnings ratio of -6.00 and a beta of 2.03.

Mineralys Therapeutics (NASDAQ:MLYSGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.02). As a group, equities analysts predict that Mineralys Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Lifesci Capital restated an “outperform” rating on shares of Mineralys Therapeutics in a report on Tuesday, March 26th. The Goldman Sachs Group assumed coverage on shares of Mineralys Therapeutics in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $30.00 price target for the company.

Get Our Latest Report on MLYS

Mineralys Therapeutics Profile

(Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

Read More

Institutional Ownership by Quarter for Mineralys Therapeutics (NASDAQ:MLYS)

Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with's FREE daily email newsletter.